News

Novartis has voluntarily pulled back on increasing prices in the U.S. to keep the cost of its medicines “reasonable” and “defensible” and to reflect their value for patients.

The state's new guidance sets guidelines for insurers on how those claims should be evaluated.

The lawsuit seeks to strike down a new law that mandates opioid manufacturers and distributors collectively pay $100 million each year to the state over the next six years.

The regulation could represent a sweeping shift in how drug prices are set in the U.S. and potentially eliminate some of the opacity that surrounds the system.

Four new bills introduced in upper chamber as House preps retirement in 'Tax Reform 2.0.'

Two approved cancer therapies, with price tags of hundreds of thousands of dollars, have roiled the insurance approval process, leading to delays and, in some cases, denials of coverage.

The number of patients with claims that exceeded $1 million grew by 87 percent between 2014 and 2017.

Partnerships, promotions, new hires from Unum, Neighborhood Trust Financial Partners, Benefitfocus & more.